Free Trial

Eliem Therapeutics (ELYM) News Today

$7.22
+0.15 (+2.12%)
(As of 07/12/2024 ET)
Eliem Therapeutics logo with Medical background
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Sees Significant Growth in Short Interest
Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 373,300 shares, an increase of 552.6% from the June 15th total of 57,200 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average trading volume of 918,600 shares, the days-to-cover ratio is presently 0.4 days.
Eliem Therapeutics logo with Medical background
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Director Buys $49,952,816.64 in Stock
Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) Director Ra Capital Management, L.P. acquired 13,008,546 shares of Eliem Therapeutics stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $3.84 per share, for a total transaction of $49,952,816.64. Following the completion of the purchase, the director now directly owns 23,521,757 shares in the company, valued at $90,323,546.88. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Down 53.5% in May
Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 59,900 shares, a decline of 53.5% from the May 15th total of 128,800 shares. Based on an average daily trading volume, of 863,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.3% of the shares of the company are sold short.
Short Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Rises By 127.2%
Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 128,800 shares, a growth of 127.2% from the April 30th total of 56,700 shares. Based on an average trading volume of 850,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.7% of the shares of the company are sold short.
Short Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Increases By 4,453.8%
Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Currently, 3.3% of the company's stock are short sold. Based on an average trading volume of 665,800 shares, the short-interest ratio is currently 0.9 days.
BML Capital Management LLC Boosts Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)
BML Capital Management LLC boosted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the comp
Eliem Therapeutics (NASDAQ:ELYM) Trading 0.5% Higher
Eliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5%
Silverarc Capital Management LLC Lowers Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)
Silverarc Capital Management LLC trimmed its holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 75.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,110 shares of the company's stock after selling
Eliem Therapeutics (NASDAQ:ELYM) Shares Up 3.5%
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 3.5%
Checkpoint Therapeutics Inc CKPT
Eliem Therapeutics Inc ELYM
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics GAAP EPS of -$0.84
SVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)
Get Eliem Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.

Catalyst Could Trigger 10,000% Crypto Gains (Ad)

Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look:

Claim your free seat by clicking here now.

ELYM Media Mentions By Week

ELYM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ELYM
News Sentiment

0.66

0.92

Average
Medical
News Sentiment

ELYM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ELYM Articles
This Week

13

0

ELYM Articles
Average Week

Get Eliem Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ELYM) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners